MetaCap

Citius Oncology (CTOR) vs iBio (IBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

iBio (IBIO) has outperformed Citius Oncology (CTOR) over the past year, losing 23.8% versus a loss of 55.4%. iBio is the larger company by market cap ($56.4 million vs $53.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTOR-55.44%IBIO-23.80%
+205%+68%-69%
Nov 21, 20251 yearNov 20, 2026
CTOR-95.01%IBIO-93.55%
+321%+103%-115%
Dec 5, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTOR versus IBIO key metrics
MetricCTORIBIO
Share price$0.5035$0.8001
Market cap$53.25M$56.37M
1-day change-10.95%-0.11%
YTD return-49.65%-58.54%
1-year return-55.44%-23.80%
5-year return—-99.76%
EPS (TTM)$-0.48$-0.27
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$100.00K
Revenue growth (YoY)—-75.00%
Net income (latest FY)$-24.76M$-33.04M
Operating margin—-35141.00%
Net margin—-33044.00%
52-week high$1.83$3.82
52-week low$0.491$0.68
Distance from 52-week high-72.49%-79.05%
Analyst consensusnonestrong_buy
Avg. price target upside+694.44%+611.16%
Average volume114.02K678.91K
Shares outstanding105.76M70.46M
Employees—23
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IBIO has outperformed CTOR by 31.6 percentage points over the past year.

About Citius Oncology

CTOR stock →

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.

Health Care · Biotechnology: Pharmaceutical Preparations

About iBio

IBIO stock →

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

CTOR vs IBIO FAQ

Which is bigger, Citius Oncology or iBio?

iBio (IBIO) is larger, with a market capitalization of $56.37M compared with $53.25M for Citius Oncology (CTOR).

Which stock has performed better over the past year, CTOR or IBIO?

IBIO returned -23.80% over the past 12 months, compared with -55.44% for CTOR (price return, excluding dividends). Past performance does not predict future results.

Are Citius Oncology and iBio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons